Carola P. Friedman, MD, FACC

1
Carola P. Friedman, MD, FACC

• Executive Medical Director
• Worldwide Consumer Medicines

7asdf
2
Conclusion

• The burden of CHD remains enormous
• People are pursuing self care options
• Pravachol 10 has a profile that is appropriate
  forOTC status
• Safety
• Meaningful LDL-C reduction
• OTC Pravachol 10 is an appropriate option for
  lower risk individuals choosing to lower their
  cholesterol
• Will result in more people on appropriate therapy
• Provide an additional approach to treat a major
  modifiable CHD risk factor
• Help close the therapeutic gap